This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Musculoskeletal disease				
Muscular dystrophy	Biglycan (BGN)	<p>Studies in mice suggest that recombinant human BGN (rhBGN) could help treat Duchenne muscular dystrophy (DMD). In the <i>mdx</i> mouse model of DMD, a single intraperitoneal dose of rhBGN decreased dystrophic muscle pathology and increased muscle function compared with a dose of vehicle control. Next steps include evaluating rhBGN in additional preclinical DMD models. Tivorsan Pharmaceuticals Inc. has rights to rhBGN, which is in preclinical development to treat DMD.</p> <p>SciBX 4(4); doi:10.1038/scibx.2011.110 Published online Jan. 27, 2011</p>	<p>Patent status undisclosed; exclusively licensed to Tivorsan Pharmaceuticals</p>	<p>Amenta, A.R. <i>et al. Proc. Natl. Acad. Sci. USA</i>; published online Dec. 27, 2010; doi:10.1073/pnas.1013067108 Contact: Justin R. Fallon, Brown University, Providence, R.I. e-mail: Justin_Fallon@brown.edu</p>